Comments
Loading...
Alnylam Pharmaceuticals (ALNY) Forecast
NewsEarningsAlnylam Pharmaceuticals (ALNY) OptionsGuidanceDividendsAnalyst RatingsInsider TradesGovernment TradesShort InterestAlnylam Pharmaceuticals (NASDAQ:ALNY) Stock Quotes, Forecast and News Summary
Alnylam Pharmaceuticals Stock (NASDAQ: ALNY) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Alnylam Pharmaceuticals (ALNY) stock?
You can purchase shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) through any online brokerage.
Who are Alnylam Pharmaceuticals (ALNY) competitors?
Other companies in Alnylam Pharmaceuticals’s space includes: BeiGene (NASDAQ:ONC), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Amgen (NASDAQ:AMGN).
What is the forecast, or price target, for Alnylam Pharmaceuticals (ALNY) stock?
Alnylam Pharmaceuticals has a consensus price target of $294.12.
What is the current price for Alnylam Pharmaceuticals (ALNY)?
The stock price for Alnylam Pharmaceuticals (NASDAQ: ALNY) is $252.005 last updated February 21, 2025 at 10:25 AM EST.
Does Alnylam Pharmaceuticals (ALNY) pay a dividend?
There are no upcoming dividends for Alnylam Pharmaceuticals.
When is Alnylam Pharmaceuticals (NASDAQ:ALNY) reporting earnings?
Alnylam Pharmaceuticals’s Q1 earnings are confirmed for Thursday, May 1, 2025.
Is Alnylam Pharmaceuticals (ALNY) going to split?
There is no upcoming split for Alnylam Pharmaceuticals.
What sector and industry does Alnylam Pharmaceuticals (ALNY) operate in?
Alnylam Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.